

Sarah Newton MP Minister for Vulnerability, Safeguarding and Countering Extremism

2 Marsham Street London SW1P 4DF www.gov.uk/home-office

Dr Owen Bowden Jones Chair, Advisory Council on the Misuse of Drugs 2 Marsham Street London SW1P 4DF

26th June 2017

Dear Owen,

ACMD further advice on Methiopropamine

I am grateful for the Advisory Council on the Misuse of Drugs' further advice dated 16 June regarding the appropriate classification for Methiopropamine ('MPA'), which is currently under a Temporary Class Drugs Order ('TCDO') due to expire on 27 November 2017.

I am pleased to note that the TCDO has been effective in abating some of the prevalence and use of MPA. I remain concerned about the harms associated with MPA which have been detailed in your report. As such, I accept your recommendation to list MPA as a Class B drug under the Misuse of Drugs Act 1971. In addition, I note your conclusion that MPA has no known medicinal or industrial use beyond research and therefore accept your recommendation to list MPA as a Schedule 1 drug under the Misuse of Drugs Regulations 2001.

I have asked my officials to commence the Parliamentary process to ensure that the necessary controls are in place prior to the expiry of the TCDO. They will also inform our key partners of the changes coming into effect.

Yours sincerely

Sarah Newton MP